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2Abstract
We used a high-titer recombinant adeno-associated virus (rAAV) vector to express wild-type or
mutant human a-synuclein in the substantia nigra of adult marmosets. The a-synuclein protein was
expressed in 90-95% of all nigral dopamine neurons and distributed by anterograde transport
throughout their axonal and dendritic projections. The transduced neurons developed severe neuronal
pathology, including a-synuclein positive cytoplasmic inclusions and granular deposits, swollen,
dystrophic and fragmented neurites, and shrunken and pyknotic, densely a-synuclein positive
perikarya. By 16 weeks post-transduction, 30-60% of the tyrosine hydroxylase positive neurons were
lost, and the tyrosine hydroxylase positive innervation of the caudate nucleus and putamen was
reduced to a similar extent. The rAAV-a-synuclein treated monkeys developed a type of motor
impairment, i.e. head position bias, compatible with this magnitude of nigrostriatal damage. rAAV
vector mediated a-synuclein gene transfer provides for the first time a transgenic primate model of
nigrostriatal a-synucleinopathy that is of particular interest since it develops slowly over time, like
human PD, and expresses neuropathological features - a-synuclein positive inclusions and dystrophic
neurites, in particular - that are similar to those seen in idiopathic PD. This model offers new
opportunities for the study of pathogenetic mechanisms and exploration of new therapeutic targets of
particular relevance to human PD.
3Introduction
DA neurodegeneration induced by MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) is
currently the best available primate model of Parkinson’s disease (PD) (see (1, 2), for a current
review). In adult monkeys, MPTP administration induces profound loss of DA neurons in the SN and
motor impairments similar to those seen in idiopathic PD. The MPTP model, however, has two
obvious limitations: First, MPTP-induced toxicity is a rapid, single-hit event, resulting in an acute
onset of neurodegeneration and neurological symptoms. Secondly, the MPTP-affected DA neurons do
not develop the progressive a-synucleinopathy, Lewy bodies and Lewy neurites in particular, which
is the characteristic hall-mark of idiopathic PD. There is thus an obvious need for a new primate
model of PD where the pathogenetic mechanisms associated with a-synuclein (a-syn) toxicity and
nigrostriatal degeneration can be studied in species close to man.
Previous studies have shown that the a-syn protein is a major component of the intraneuronal
protein aggregates, Lewy bodies and Lewy neurites, that are pathological hallmarks of the disease (3,
4). Moreover, point mutations in the a-syn gene have been shown to cause familiar PD (5, 6),
suggesting that abnormal processing and/or function of a-syn may trigger the neurodegenerative
process. Although a-syn is expressed in neurons throughout the nervous system, neurodegeneration in
PD is remarkably selective and is most prominent in the dopaminergic neurons of the substantia nigra
(SN). Recent studies suggest that this selective vulnerability may be due to interaction of a-syn with
intracellular dopamine (DA), oxidative stress and DA-dependent free radical damage (7-10). This
interaction probably explains why dopaminergic neurons are affected by a-syn at expression levels
that are non-toxic to other types of cells (10-13).
4These in vitro data raise the possibility to generate transgenic models of PD by overexpression
of the a-syn protein in the nigrostriatal DA neurons. This approach has given promising results in
Drosophilia (14). Nevertheless, the attempts made so far in mice, using standard transgenic
technology, have been disappointing. In the transgenic mouse strains generated to date, wild-type or
mutated human a-syn have been expressed under neuron-specific promoters, although, a-syn
accumulation, a-syn-positive inclusions and signs of neuronal injury have been wide-spread, no
significant nigral pathology or cell loss have been detected in any of these mice (15-21). Recently,
however, direct gene transfer by means of viral vectors has emerged as an interesting alternative to
the standard transgenic approach. Recombinant adeno-associated virus (rAAV) and lentivirus (rLV)
vectors in particular, are useful for this purpose since they transduce non-dividing neurons with high
efficiency in the CNS, and are integrated and stably expressed without any signs of inflammatory or
immune reactions (22, 23). These vector systems can be targeted to specific subregions of the CNS,
and in contrast to standard transgenic technology, they offer a transgenic approach that can be applied
in adult animals and in other species than mice, such as rats and primates.
The rAAV vectors are of special interest in the context of PD because of their exceptionally
high affinity for nigral DA neurons. In a previous study (24) we have shown that the rAAV vector
system can be used to overexpress wild-type or mutant a-syn in the nigrostriatal neurons in adult rats,
and that this is accompanied by the development of a pronounced a-synucleinopathy, including the
appearance of a-syn positive cytoplasmic inclusions and dystrophic neurites, a gradual loss of 30-
80% of the nigral DA neurons and PD-like behavioral improvements.
In the present study we have applied this rAAV-a-syn vector construct to express human a-
syn in the nigrostriatal DA neurons in a small non-human primate, the common marmoset. We report
that the rAAV vector is equally effective in transducing the pars compacta neurons of the primate SN,
5and show that overexpession of either wild-type or mutant human a-syn is sufficient to induce a PD-
like neuropathology in the primate nigrostriatal system, accompanied by DA neuron cell loss and
signs of motor impairments.
6Experimental Protocols
rAAV vectors. The rAAV-CBA-a-syn, rAAV-CBA-mu-a-syn, and rAAV-CBA-GFP vectors were
produced using a double transfection method with rAAV plasmids and a helper plasmid containing
the necessary gene products normally provided by adenovirus (25), and purified as described (26).
The final titers were 8.2x1011, 1.4x1012 and 1.5x1011 infectious units (IU) /ml, respectively, for the
three vectors, as determined by an infectious center assay (27). The vectors express the transgene
from a hybrid promoter consisting of an enhancer element from the CMV promoter followed by the
chicken b-actin promoter containing a rabbit b-globin intron, termed CBA (28).
Animals and surgery. All procedures were carried out under a Project Licence in accord with the
U.K. Animals (Scientific Procedures) Act 1986. Eight adult common marmosets (Callithrix jacchus),
4 males and 4 females, were used. All were laboratory-bred, aged 65-72 months and weighed 340-
380g at the start of the experiment. The monkeys were housed in pairs with both members of the pair
receiving the same type of rAAV vector injection. Two monkeys received injections of the rAAV
vectors encoding the wild-type human a-syn, two received A53T mutated human a-syn, and four
received a control vector encoding the green fluorescent protein (GFP). In one of the rAAV-wt-a-syn
injected animals the injections failed; this animal was not included in the further analysis.
For surgery, the marmosets were anaesthetized with alphaxalone-alphadone (Saffan; Schering
Plough Ltd, Welwyn Garden City, UK; 0.5 ml of 12 mg/ml, i.m.). A supplementary dose of 0.3 ml
Saffan was given during surgery if necessary. Infusions of 3 ml rAAV were made unilaterally at each
of 2 sites in the right SN: AP 5.5, L -2.5, V 6.6 and AP 4.0, L -2.5, V 6.6 (co-ordinates derived from
the stereotaxic atlas of Stephan et al. (29)). The injections were made at a rate of 0.25 ml/min using a
29g injection needle that was left in place for a further 4 min after each injection. Following surgery
7the monkeys were given an analgesic (Finadyne; Schering-Pough Animal Health, Mildenhall, UK; 0.1
mg/kg, subcutaneously) and kept warm in an incubator until well enough to be returned to their home
cage, usually later that day.
Behaviour. Changes in motor behaviour over time were monitored by amphetamine-induced
rotation and a head position bias test (30, 31). In the latter test, the direction of the head relative
to the body axis (ipsi- or contralateral to the injected side or straight ahead) was scored every
second over 3 x 1 min periods. The time difference (ipsi-contra) was used as a measure of head
position bias. Tests were conducted pre-operatively, at 3 weekly intervals and 16 weeks after the
AAV infusions.
Histology. The monkeys were perfused for histological analysis at 3-16 weeks after vector
injection. Following premedication with 0.05 ml ketamine (Vetalar; Shering-Plough, Welwyn
Garden City, UK; 100 mg/ml, i.m.) and under deep anaesthesia with 0.8 ml sodium
pentobarbitone (200 mg/ml, i.p.), the monkeys were perfused transcardially with 300 ml
phosphate-buffered saline (PBS) followed by 1000 ml of 4% paraformaldehyde in PBS. The
brains were placed in 4% paraformaldehyde solution for 24 hours, after which they were
transferred to 30% sucrose solution in PBS. Immunohistochemical stainings were performed on
free-floating sections using antibodies raised against tyrosine hydroxylase (TH) (Rabbit IgG,
1:250, Pel-Freez, AR, USA), green fluorescent protein (GFP) (Rabbit IgG, 1:20000, Abcam,
Cambridge, UK), the vesicular monoamine transporter-2 (VMAT-2) (Rabbit IgG, 1:2000,
Chemicon, Temecula, CA, USA), Hu (Mouse IgG, 1:1000, courtesy of Dr. Steven A. Goldman),
and human a-syn (Mouse IgG, 1:16000, courtesy of Dr. Virginia M. Lee). Incubation with
primary antibodies was followed with the appropriate secondary antibodies conjugated to biotin,
and avidin-biotin-peroxidase complex (ABC Elite, Vector Laboratories, CA, USA), visualized
8with 3,3’-diaminobenzidine, mounted on chrome-alum coated glass slides and coverslipped. For
co-localization of GFP and TH, incubation with anti-TH primary antibody was followed by
donkey anti-rabbit antibody conjugated to Cy3 (red) and GFP was visualized using confocal
microscopy by its native fluorescence in the green channel. An additional series of sections were
stained for cresyl violet.
The total number of TH-positive and VMAT-2-positive neurons in the SN were estimated in separate
series of sections according to the optical fractionator principle (32), using the Olympus CAST
system (Olympus Denmark A/S, Albertslund, Denmark). Every eighth section covering the entire
extent of the SN was included in the counting procedure. The borders of the SNpc were defined as
follows: the medial border between the ventral tegmental cell group and the pars compacta region was
just lateral to the roots of the third nerve. At the most caudal level, the pars compacta was defined as
the dense TH cell group ventral to the medial lemniscus and the retrorubral area. The TH positive
cells in the pars retriculata (and therefore dorsal to the cerebral peduncle) were included in the cell
counts. This definition led typically to 7-8 sections per monkey being measured. A coefficient of error
of <0.10 due to the estimation was accepted.
9Results
The animals received injections of high-titer rAAV-a-syn and rAAV-GFP vectors unilaterally at two
sites (2x3 ml) in the SN and were perfused at 3 weeks (n=2 from GFP group), and 16 weeks (n=3
from a-syn group and n=2 from GFP group) after the transduction. In the rAAV-GFP injected
animals 90-95% of the TH positive cells were found to express GFP at all rostrocaudal levels
throughout the SN, indicating that the nigral DA neurons were very efficiently transduced in the
marmoset brain (Fig 1A,B). Most of the transduced cells in the SN was confined to the pars
compacta, but some GFP expressing cells were also found in the ventral tegmental area (VTA). In
addition, GFP-expressing cells occurred in the SN pars reticulata, ventral to TH-positive cells, and
dorsally in the mesencephalic tegmentum (Fig. 1A). In the two animals killed at 3 weeks following
rAAV-GFP injection transgene expression was confined to the cell bodies and proximal axons within
the SN pars compacta, as well as the dendrites extending into the pars reticulata. At 16 weeks,
transgene expression was maintained at a high level in the SN. In addition, anterogradely transported
GFP protein could now be visualized also along the entire nigrostriatal pathway and in axon terminals
throughout the striatum, including nc. accumbens and olfactory tubercle (Fig 1C, D). No signs of
damage or degeneration could be detected in the GFP-transduced cells or their processes with any of
the markers used (TH, VMAT-2, Hu, and CV; data not shown).
In animals injected with either of the two a-syn vectors, by contrast, there were clear signs of
degeneration in the nigrostriatal DA neurons. The total number of TH-positive cells in the injected
SN, as determined by stereology, was decreased by 32-61% in the three injected animals (from an
average of 47,106 cells on the contralateral untreated side, to an average of 26,797 on the injected
side; cf Fig. 2A and B). The same magnitude of cell loss (41-62%; from 43,034 cells on the control
side to 23,214 cells on the injected side) was observed also in sections stained for the vesicular
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monoamine transporter, VMAT-2, arguing against the possibility of a selective downregulation of TH
protein in the a-syn expressing cells (Fig. 2C-E). The loss of dopaminergic cells was further
supported by a similar reduction in the number of neuronal profiles within SN pars compacta in
sections stained for the pan-neuronal marker, Hu, or with cresyl violet (Fig 2F-I). Cell death was most
prominent in the central part of the SN but was seen at all rostrocaudal levels. Loss of TH- and
VMAT-2-positive cells was observed also in the VTA, though of lesser magnitude than in SN. No
such cell loss was observed in any of the rAAV-GFP treated control monkeys (Fig. 2A).
Close examination of the SN transduced with either wild-type or mutant a-syn revealed signs
of degeneration and ongoing pathology in the neurons of the pars compacta, including a-syn positive
cytoplasmic inclusions and granular deposits (Fig. 3F), a-syn- and TH-positive swollen, dystrophic
and fragmented neurites (Fig. 3C,G,H), and shrunken, pyknotic perikarya with dense a-syn
immunoreactivity (Fig. 3B,C). Also the dendrites projecting into the pars reticulata were severely
damaged (compare Fig.3A and B, 3J), and a-syn- and TH-positive inclusions and swollen axons
could be traced in large numbers along the nigrostriatal pathway (Fig. 3D,E). Many of the surviving
nigral cells, however, still expressing a-syn, had a normal intact appearance (Fig 3B). In these cells
the a-syn immunoreactivity had an even, diffuse cytoplasmic distribution, suggesting that they had
escaped the a-syn-induced toxic impact.
In the rAAV-a-syn injected monkeys, degenerative changes in the axon terminals in the
striatum could be visualized both with TH (Fig. 4C) and VMAT-2 antibodies (Fig 4D). None of these
changes were seen in the animals injected with the rAAV-GFP control vector (Fig. 4A,B). A
substantial loss of TH and VMAT-2 positive fibers, in the order of 40-50%, ocurred throughout the
caudate nucleus and putamen, while the innervation in the ventral striatal and limbic regions,
including nc accumbens and the olfactory tubercle, was relatively spared (Fig 4C, compare E and F).
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Swollen axons and pathological inclusions were observed in the remaining sparse TH-positive
innervation in the striatum (Fig 4F,G), and also within the internal capsule (not shown).
In the behavioural tests, amphetamine-induced rotation did not show any consistent changes at
any time point (data not shown). In the head position test, the pre-injection average scores (±SEM) for
the rAAV-a-syn and rAAV-GFP groups were +0.5±5.4 and +9.4±2.1 sec, respectively. At 3 weeks
post-injection, i.e. at the time when transgene expression in the AAV-infected cells is fully developed
(33-36), the animals in the rAAV-a-syn group showed a marked bias in the direction away from the
injected hemisphere (-33.0 ±5.7 sec, as compared with +7.5±2.1 sec in the rAAV-GFP group). At 6
weeks post injection this contralateral bias was reversed to an ipsilateral bias (+17.7±1.7 sec), as
would be expected from animals with loss of DA innervation in the striatum. This bias persisted until
the end of the experiment at 16 weeks after transduction and was especially strong in two of the three
rAAV-a-syn animals (+40.5, +22.3, -14 sec, respectively), while the rAAV-GFP injected animals
showed no such bias (+5.5 and –7.3 sec, respectively).
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Discussion
The cellular changes induced by overexpression of a-syn in nigral DA neurons reproduces some of
the cardinal neuropathological features of human PD, including a-syn positive cytoplasmic inclusions
and a-syn positive swollen and dystrophic neurites, associated with degenerative changes in TH-
positive axons and dendrites. In the rat, this a-synucleinopathy is a slowly developing process that
starts at about 3 weeks after transduction and is fully developed by 2 months. At that time-point 30-
80% of the nigral DA neurons and 25-90% of the striatal DA innervation are lost. A similar, 30–60%,
loss of TH- and VMAT-2-positive neurons in the SN, and a 40-50% reduction in TH-(and VMAT-2)
positive innervation throughout candate nucleus and putamen was observed in the rAAV-a-syn
treated monkeys. Similar to idiopathic PD the TH-positive neurons in the VTA, and the associated
innervation in limbic forebrain regions, were relatively spared. These monkeys displayed a type of
motor impairment, i.e. head position bias, that is compatible with the observed magnitude of nigral
DA neuron cell loss. This side bias developed slowly, between 3 and 6 weeks after transduction, and
was maintained in 2 of the 3 animals until the end of the experiment (at 16 weeks).
The nigral DA neurons appear to be particularly sensitive to a-syn overexpression.
Interestingly, however, in both in rats and monkeys part of the transduced DA neurons survived long-
term without any clear signs of damage, despite a maintained expression of the transduced a-syn
protein, while others displayed signs of cellular and neuritic pathology suggestive of an ongoing
neurodegenerative process. This variable vulnerability may be explained by the observation that a-
syn toxicity is closely linked to the level of oxidative stress, and that DA neurons may be particularly
sensitive due to interaction of a-syn with intracellular DA and DA-dependent oxidative mechanisms
(7, 10, 11, 37, 38). It is worth noting that with the current technique the level of transgene expression
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will vary among the infected cells since neurons close to the injection site may receive more copies of
the recombinant virus. However, it is likely that not only the level of a-syn expression but also the
level of oxidative stress, which may vary from cell to cell, will determine the impact on the
transduced cell. Previous in vitro studies (see, e.g., (11, 38, 39)) have shown that the A53T and A30P
mutants of human a-syn may be more toxic and make the transduced cells more vulnerable to
oxidative stress, than the wild-type form. In the present model, as in some other in vivo experiments
(14, 17, 19, 20, 24, 40), both the wild-type and the A53T mutant a-syn were highly toxic. In the
absence of dose-response data, however, we cannot determine whether the two forms may differ in
potency.
Neurodegeneration in PD is likely to depend on an interaction between a-syn (and the
ubiquitin-proteasome pathway), oxidative stress and mitochondrial impairment. Current animal
models of PD successfully replicate the two latter mechanisms: 6-hydroxydopamine-induced toxicity
mediated by oxidative damage, and MPTP- and rotenone-induced toxicity, mediated by chronic
inhibition of mitochondrial complex I (1, 41). Targeted overexpression of a-syn in nigral DA neurons
by rAAV vectors provides a new model of nigrostriatal a-synucleinopathy and a-syn-induced
nigrostriatal neurodegeneration that will be a valuable complement to the existing ones. The
advantage of this a-synucleinopathy model is that it is chronic and progressive, like human PD, and
that it develops neuropathological features, in particular a-syn positive inclusions and dystrophic
neurites, that are similar - albeit not identical - to those seen in idiopathic PD. Moreover,
neurodegeneration and behavioral impairments evolve over a relatively short period, 6–8 weeks after
transduction as determined in the rat (24), which is advantageous for experimental studies. Compared
to standard transgenic mouse technology vector mediated transgenesis has a particular attraction in
that the transgenic protein can be delivered to adult animals at any time during the life-span; that it
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can be targeted to specific subsets of neurons; that it can be applied uni- or bilaterally, as desired; and
that it can be employed also in primates. Viral vectors, and the new generation high-titer rAAV
vectors in particular, provide new efficient tools for cell-specific, targeted transgenesis in the brain.
The feasibility of using this approach in primates, as shown here, opens entirely new possibilities for
the generation of transgenic primate models of neurodegenerative diseases, and for in vivo studies of
pathogenetic mechanisms. Since rAAV vectors can be administered repeatedly to the same cells, they
will be interesting also as tools for the expression of genes and intracellular factors that may block or
interfere with critical pathogenetic processes (such as formation of toxic fibrils or protein aggregates
in rAAV-a-syn treated animals) and for the exploration of new molecular targets for therapeutic
purposes.
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Figure Legends
Figure 1. Photomicrographs showing the expression of the GFP transgene in monkeys injected
with the control vector. (A,B) GFP was expressed in the vast majority of the neurons in SN pars
compacta, and some cells dorsally in the mesephalic tegmentum and ventrally in the SN pars
reticulata (A). The transgenic GFP protein was transported along the axons of the nigrostriatal
projection system to the caudate nucleus, putamen and lateral olfactory tubercle, whereas the
projections to the medial olfactory tubercle and the nc accumbens was not labeled to the same
extent (C; the non-injected control side is to the left). The density of GFP-expressing fibers in the
striatum is shown in panel D. Scale bar in A=0.5mm, B,D= 50, C=1mm
Figure 2. Photomicrographs showing the TH (A,B), VMAT-2 (C-E), cresyl violet (F,G) and Hu
(H,I) stained sections at the level of SN. In the rAAV-GFP treated animals both TH (A) and
VMAT (compare C and D) staining showed normal numbers and distribution of nigral
dopaminergic cells. In the rAAV-a-syn injected animals, by contarts, a clear loss of cells was
seen both with TH (B) and VMAT-2 stainings (compare C and E). Scale bars in A,B=0.5mm, C-
E=300µm. CP: cerebral peduncle, SNc: substantia nigra pars compacta, SNr: substantia nigra
pars reticulata, VTA: ventral tegmental area.
Figure 3. Nigral degeneration in the rAAV-a-syn injected animals. Pathological profiles in the
SN was seen both with TH (A,B,J) and a-syn immunoreactivity (C-I). Extensive cellular
degeneration in the SN pars compacta, as visualized by TH immunoreactivity also lead to
prominent dendritic abnormalities and loss of dendrites in the SN pars reticulata (B, J). Affected
but surviving cells in SN pars compacta were shrunken (C), contained numerous inclusions
within the cytoplasm and proximal neurites (F), as well as in axons within pars compacta (G,H)
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and along the nigrostriatal bundle (I). Numerous pathological fibers with prominent inclusions
were observed in the cerebral puduncle (compare D and E).
Figure 4. Photomicrographs illustrating the axonal fiber innervation in the striatum visualized
with TH (A,B,E-G) and VMAT-2 (B,D) immunohistochemistry. While expression of GFP
protein did not alter the density of TH and VMAT-2-positive fiber innervation in the striatum
(A,B), the expression of a-syn lead to prominent loss of fibers both in cudate nucleus and
putamen in the transduced hemisphere, as compared with the contralateral intact side (C,D).
Remaining TH-positive fibers in the a-syn treated animals were sparse (compare E and F) and
contained inclusions (G).
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